Skip to main content
SpringerLink
Log in

Separate cost review for cancer drugs "needs closer scrutiny"

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • McDonald H, et al. Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes? PharmacoEconomics : 26 Nov 2014. Available from: URL: http://doi.org/10.1007/s40273-014-0238-7

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Separate cost review for cancer drugs "needs closer scrutiny". PharmacoEcon Outcomes News 717, 13 (2014). https://doi.org/10.1007/s40274-014-1738-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1738-6

Search

Navigation